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Abstract: Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of
multiple myeloma (MM). It seems to determine cardiovascular toxicity, primarily arterial hypertension.
No predictive factors for cardiovascular adverse events (CVAEs) are known in patients affected
by multiple myeloma treated with carfilzomib. We evaluated the role of cardiovascular organ
damage parameters to predict CVAEs in MM patients taking carfilzomib. Seventy patients affected
by MM were prospectively enrolled. A comprehensive cardiovascular evaluation was performed
before carfilzomib therapy; they underwent a transthoracic echocardiogram and the assessment of
carotid-femoral pulse wave velocity. All the patients were followed up (FU) to determine the incidence
of CVAEs. The mean age was 60.3± 8.2, and 51% were male. The median FU was 9.3 (4.3; 20.4) months.
A proportion of 33% experienced CVAEs, 91% of them had uncontrolled hypertension, 4.5% acute
coronary syndrome, and 4.5% cardiac arrhythmias. Subjects with CVAEs after carfilzomib treatment
had significantly higher blood pressure values, left ventricular mass (98 ± 23 vs. 85 ± 17 g/m2,
p = 0.01), and pulse wave velocity (8.5 ± 1.7 vs. 7.5 ± 1.6 m/s, p = 0.02) at baseline evaluation compared
to the others. Furthermore, baseline uncontrolled blood pressure, left ventricular hypertrophy, and
pulse wave velocity ≥ 9 m/s were able to identify patients at higher risk of developing CVAEs during
FU. These preliminary findings indicate that blood pressure control, left ventricular mass, and pulse
wave velocity may predict CVAEs in MM patients treated with carfilzomib.
Keywords: cardio-toxicity; multiple myeloma; arterial hypertension; cardiovascular organ damage;
cardiovascular adverse event
1. Introduction
Carfilzomib is a second-generation proteasome inhibitor approved for the treatment of multiple
myeloma (MM) that is demonstrated to improve the overall rate response and progression-free survival
in MM patients compared to other chemotherapeutic strategies [1–3]. However, the incidence of
cardiovascular adverse events (CVAEs) has been increasing since carfilzomib introduction: arterial
hypertension and congestive heart failure, the most common CVAEs, are experienced by respectively
12% and 4% of MM patients treated with this new proteasome inhibitor [4,5]. The pathogenic
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mechanism underling carfilzomib-induced cardiovascular toxicity has not been clarified yet. However,
myocardial cells seem to be sensitive to proteasome inhibitors because of the essential role of the
ubiquitine-proteasome system for their intracellular metabolism [6]. Furthermore, proteasomal
inhibition leads to the down regulation of eNOS (endothelial nitric oxide synthase) activity, which is
responsible for decreased endothelial NO levels and thus development of arterial hypertension [7].
So far, no predictive factors for the development of cardiovascular toxicity have been identified in
patients undergoing carfilzomib therapy [8].
Left ventricular mass is a morphological parameter that describes cardiac remodeling and the
presence of left ventricular hypertrophy is a sign of cardiac organ damage [9]. Likewise, pulse
wave velocity is the gold standard measurement of arterial stiffness and its use is suggested by
current guidelines to determine vascular organ damage [9–11]. Left ventricular mass and pulse
wave velocity are both independent predictors of CVAEs in the general population and specific
subgroups [12–15]. Recent studies have suggested a correlation between left ventricular hypertrophy
and the development of CVAEs during follow up in MM patients treated with the new proteasome
inhibitor [16], but further analysis is required to define the potential predictive role of these parameters
in this oncological population.
The aim of our study was to determine if parameters commonly used to assess cardiovascular
organ damage are able to predict the incidence of CVAEs in MM patients undergoing treatment
with carfilzomib.
2. Methods
From April 2017 to April 2018, 70 MM patients, followed by the Myeloma Unit (“Città della
Saluta e della Scienza”, Turin), were prospectively enrolled. The inclusion criteria were the history of
new diagnosed/refractory/relapsed MM in patients with clinical indication to carfilzomib treatment,
and age ≥ 18 years. Patients were excluded if they had cardiac amyloidosis, were aged < 18 years,
and denied informed consent.
The study protocol was approved by the ethic committee of our hospital “A.O.U. Città della Salute
e della Scienza” of Turin (Protocol Number 0038655) and each patient signed a written consent form.
The enrolled patients underwent a comprehensive cardiovascular evaluation c/o our Echo
Lab (Hypertension Unit, “Città della Salute e della Scienza”, Turin) before the beginning of
carfilzomib infusions. We collected anamnestic information and performed a complete examination,
including measurement of office blood pressure values, ambulatory blood pressure monitoring,
electrocardiogram, transthoracic echocardiogram, and evaluation of carotid-femoral pulse wave
velocity. Antihypertensive treatment was optimized in patients with uncontrolled blood pressure
values, since office blood pressure < 140/90 mmHg was required to start every carfilzomib infusion.
Office blood pressure (BP) measurements were performed according to the current guidelines [9,17].
An automatic sphygmomanometer was used (Omron, M10-IT model). Three blood pressure values
were assessed three consecutive times with measurements 1–2 min apart and the mean value was
recorded and used for subsequent analysis. Optimal office blood pressure control was defined as the
average BP < 140/90 mmHg.
Every patient underwent an ambulatory blood pressure monitoring (ABPM) according to the
current recommendations [17]. A validated blood pressure measuring device (Takeda TM2430, A&D
Company Ltd., Tokyo, Japan) was worn by the patients at the time of the visit and removed after a
24-h recording period. The device was set as to perform blood pressure measurements every 15 min
for the entire 24 h period and the patients were asked to perform their usual daily activities during
the exam. We obtained 24-h/day-time/night-time systolic, diastolic, and mean blood pressure values.
Optimal ABPM blood pressure control was defined as the average 24-h BP < 130/80 mmHg, day-time
BP < 135/85 mmHg, and night-time < 120/70 mmHg.
Every patient underwent a transthoracic echocardiogram (TTE) to evaluate cardiac organ damage.
The exam was performed at rest with the patient lying in the left lateral decubitus position. Standard
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2D-TTE images were acquired with an iE33 ultrasound machine (Philips Medical System, Andover,
MA, USA) equipped with a sector probe (S5-1 transducer). Conventional parameters were assessed
according to the current guidelines [18,19]. Left ventricular (LV) diameters and walls thickness were
measured in parasternal long-axis view. LV geometry was defined by calculating left ventricular mass
(LVM, obtained using the Deveraux formula indexed to both body surface area and height elevated 2.7)
and relative wall thickness (RWT, obtained dividing the double of the LV inferolateral wall thickness
by the LV internal diameter at end-diastole). Left ventricular hypertrophy (LVH) was diagnosed with
an LV mass ≥115 g/m2 (≥49 g/m2.7) and ≥95 g/m2 (≥47 g/m2.7) respectively in men and women. LV
volumes were assessed through the Simpson’s Biplane technique from apical 4- and 2-chamber views
and indexed to body surface area, then used to evaluate LV systolic function as LV ejection fraction
(EF). LV diastolic function was defined through the evaluation of early diastolic Tissue Doppler (TDI)
velocities (e’ waves) of septal and lateral mitral annulus, mitral valve inflow (E and A wave velocity),
tricuspid regurgitation peak velocity, left atrial volume (indexed to body surface area) and E/e’ ratio,
according to the current recommendations [19]. Speckle tracking analysis was performed according to
the current guidelines with a dedicated software (Automated Cardiac Motion Quantification, QLAB
Cardiac Analysis, Philips, Andover, MA, USA): global longitudinal strain (GLS) was computed offline
from standard 2D images of the LV in apical views (4-, 2-chamber, and long axis views) with manual
adjustment of endocardial borders when needed following standardized protocols [20].
Carotid-femoral pulse wave velocity (cf-PWV) was measured to assess arterial stiffness. cf-PWV
measurement was performed according to the current guidelines [11] with a validated instrument
(Sphymocor system Atcor Medical, Sydney, Australia). A single applanation tonometer was used
to obtain and record carotid and femoral pulse waveforms. The cf-PWV was calculated as the ratio
between the distance covered by the waves and the time delay measured between the feet of the two
waveforms. The mean of at least two cf-PWV measurements was considered for subsequent analysis.
2.1. Follow Up
The incidence of CVAEs during and after carfilzomib treatment was determined through periodic
review of patient hematologic reports or phone calls.
CVAEs were assessed and graded according to the Common Terminology Criteria for Adverse
Events version 5.0 (CTCAE 5.0) [21]: particularly we included arterial hypertension, heart failure,
myocardial infarction, chest pain, dyspnea, arrhythmia, cardiac arrest, as previously reported in
literature [5]. The “arterial hypertension” event referred to patients who developed arterial hypertension
during carfilzomib treatment or hypertensive patients who had a rise in blood pressure levels during
chemotherapy. Among these patients, we identified the ones who experienced an increase in blood
pressure values requiring an intensification of the anti-hypertensive therapy before carfilzomib
treatment and patients who had uncontrolled hypertension and needed a temporary interruption of
carfilzomib infusions.
When feasible, a second clinical evaluation was planned after 6 months from carfilzomib treatment
start to assess blood pressure control and optimize antihypertensive treatment if required.
2.2. Statistical Analysis
Statistical analysis was performed by using SPSS program (IBM SPSS Statistics, Version 22.0.0.0,
IBM Corp., Armonk, NY, USA). The Kolmogorov Smirnov test was chosen to evaluate the distribution
of the data. Quantitative variables were expressed as mean values and standard deviations or median
values and interquantile ranges, according to their distribution. Qualitative variables were expressed
as absolute values and percentages. Comparison between groups was performed with Student’s t-test
and Chi-Square test for quantitative and qualitative variables, respectively. Kaplan Meier curves were
obtained to investigate parameters associated with a higher risk of developing CVAEs. A p-value < 0.05
was assumed as level of statistical significance.
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3. Results
The general characteristics of our cohort are shown in Table 1.
Table 1. General characteristics, cardiovascular risk factors, and oncological history.
Variable Population n = 70
Age, years 60.3 ± 8.2
Male sex, n (%) 36 (51.4)
Weight, Kg 73.3 ± 15.2
Height, cm 163 ± 11
BSA, m2 1.78 ± 0.22
BMI, Kg/m2 27.6 ± 4.7
Cardiovascular risk factors
Arterial hypertension, n (%) 26 (37.1)
Obesity, n (%) 22 (31.4)
Coronary artery disease, n (%) 2 (2.9)
Diabetes, n (%) 7 (10)
Chronic renal failure, n (%) 6 (8.6)
Dyslipidemia, n (%) 8 (11.4)
Active smoking/previous smoking, n (%) 5 (7.1)/24 (34.3)
Oncological history
MM duration, years 4.3 ± 3.6
Relapsed/Refractory MM, n (%) 63 (90)
Previous therapy
Antracyclines, n (%) 26 (37.1)
Alkylating agents, n (%) 59 (84.3)
Immunomodulating agents, n (%) 42 (60)
Bortezomib, n (%) 56 (80)
MM staging
DS: stage I-I–III (%) 9.1-27.3–63.6
ISS: stage I-I–III (%) 53.5-30.2–16.3
Total carfilzomib dose, mg/m2 665 [295; 1 082]
* Quantitative values are expressed as mean ± SD or median [interquantile range]. BSA = body surface area;
BMI = body mass index; MM = multiple myeloma; DS = Durie-Salmon classification; ISS = International Staging System.
Mean age was 60.3 ± 8.2 years and 51.4% were male. In total, 37% of patients had a history of
arterial hypertension. Other concurrent cardiovascular risk factors were obesity (31.4%), dyslipidemia
(11.4%), diabetes (10%), and chronic renal failure (8.6%).
Mean MM duration was 4.3 ± 3.6 years. Most subjects (63, 90%) had relapsed or refractory
MM and had already undergone chemotherapy with anthracyclines, immunomodulating agents,
alkylanting agents and bortezomib. Median number of previous chemotherapeutic treatment lines
was 2.5 (2;3). MM was mainly diagnosed at stage III according to the Durie-Salmon classification and
stage I according to the International Staging System (ISS).
Mean office blood pressure (BP) and ABPM values were within normal limits (Table 2); however,
50% of patients did not have a baseline optimal blood pressure control and needed antihypertensive
treatment introduction or adjustment.
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Table 2. Office blood pressure and ambulatory blood pressure monitoring (ABPM).
Office Blood Pressure Population (n = 70)
Office BP, mmHg 131 ± 18 / 77 ± 11
Office BP < 140/90 mmHg, n (%) 35 (50)
Antihypertensive drugs, n 1 [1;2]
ABPM
24 h SBP, mmHg 120 ± 11
24 h DBP, mmHg 71 ± 7
24 h MBP, mmHg 88 ± 8
24 h HR, bpm 77 ± 13
24 h SD, mmHg 14 ± 5
Day-time SBP, mmHg 124 ± 12
Day-time DBP, mmHg 75 ± 8
Day-time MBP, mmHg 92 ± 8
Day-time HR, bpm 80 ± 14
Day-time SD, mmHg 13 ± 6
Night-time SBP, mmHg 111 ± 13
Night-time DBP, mmHg 64 ± 7
Night-time MBP, mmHg 80 ± 9
Night-time HR, bpm 70 ± 13
Night-time SD, mmHg 10 ± 4
Dipping, % 11 ± 7
* Quantitative values are expressed as mean ± SD or median [interquantile range]; ABPM = ambulatory blood
pressure monitoring; SBP = systolic blood pressure; DBP = diastolic blood pressure; MBP = mean blood pressure;
HR = heart rate; SD = standard deviation.
TTE showed an average left ventricular mass within normal limits (90± 20 g/m2), with a prevalence
of left ventricular hypertrophy (LVH) of 31.4%. Mean EF and GLS values were normal (EF 63 ± 7%,
GLS −20.86 ± 2.34%). Parameters describing left ventricular diastolic function did not show any
alteration, except for a mild reduction in septal and lateral e’ velocities. Finally, no vascular organ
damage appeared in our cohort by evaluating cf-PWV (mean cf-PWV 7.8 ± 1.7 m/s).
Median follow up was 9.3 [4.3; 20.4] months. A total of 23 patients (32.9%) experienced CVAEs
during follow up, within 3.6 [0.9; 6.1] months from carfizomib treatment start (Table 3): of these, 17 (74%)
experienced increase in blood pressure values to > 140/90 mmHg requiring antihypertensive treatment
intensification, 4 (17%) had uncontrolled blood pressure values requiring a temporary interruption of
carfizomib treatment; finally, 1 patient (4.5%) had a non-ST-elevated myocardial infarction and 1 (4.5%)
developed atrial fibrillation. According to the CTCAE 5.0 severity classification [20], most CVAEs were
grade 1–2 (18, 78%), only 22% (5 events) were grade ≥ 3.
We divided our population into 2 groups based on the incidence of CVAEs during follow up
(Table 4). No significant differences in age, sex, anthropometric variables, traditional cardiovascular risk
factors, MM characteristics (duration, previous treatments, total carfilzomib dose) were seen between
groups. However, baseline blood pressure control was significantly worse in patients who experienced
CVAEs. Cardiovascular organ damage was significantly different, too (Figure 1): left ventricular mass
and the prevalence of left ventricular hypertrophy were higher in the group of subjects with CVAEs
(LVMi 98 ± 23 vs. 85 ± 17 g/m2, p = 0.01; LVH 52.2% vs. 21.7%, p = 0.01); furthermore, cf-PWV was
higher in patients with CVAEs (8.5 ± 1.7 m/s vs. 7.5 ± 1.6 m/s, p = 0.02). However, no differences in
baseline GLS values were seen between groups. Blood pressure control and cardiovascular organ
damage were similar in patients who had grade 1–2 and grade ≥ 3 CVAEs.
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Table 3. Cardiovascular adverse events during and after carfilzomib treatment.
Event All Events Severe Events, Severity Score ≥ 3 *
Arterial hypertension 21 (30) 4 (5.6)
- requiring intensification of antihypertensive
therapy during carfilzomib treatment, n (%) 17 (24.3) 2 (2.8)
- requiring a temporary interruption in
carfilzomib infusions, n (%) 4 (5.7) 2 (2.8)
Heart failure, n (%) 0 (0) 0 (0)
Myocardial infarction, n (%) 1 (1.4) 1 (1.4)
Chest pain, n (%) 0 (0) 0 (0)
Dyspnea, n (%) 0 (0) 0 (0)
Arrhythmias, n (%) 1 (1.4) 0 (0)
Valvular heart disease, n (%) 0 (0) 0 (0)
Pulmonary hypertension, n (%) 0 (0) 0 (0)
Thromboembolic events, n (%) 0 (0) 0 (0)
Cardiac arrest, n (%) 0 (0) 0 (0)
Total events, n (%) 23 (32.9) 5 (7.2)
* Defined according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events).
Table 4. Comparison between patients with and without cardiovascular adverse events (CVAEs) during
follow up.
General Characteristics and
Comorbidities
CVAE−
(n = 47)
CVAE+
(n = 23) p Value
Male sex, n (%) 24 (51.1) 12 (52.2) 0.93
Age, year 60.4 ± 7.8 60.1 ± 9.1 0.91
BMI, Kg/m2 27.2 ± 4.4 28.5 ± 5.1 0.25
Arterial hypertension, n (%) 16 (34) 10 (43.5) 0.44
Diabetes, n (%) 4 (8.5) 3 (13) 0.52
Dyslipidemia, n (%) 4 (8.5) 4 (17.4) 0.27
Chronic renal failure, n (%) 4 (8.5) 2 (8.7) 0.98
Multiple myeloma
Total carfilzomib dose, mg/m2 708 (428; 1108) 540 (103; 1118) 0.19
Office Blood pressure and ABMP
SBP, mmHg 127 ± 18 141 ± 19 0.03
DBP, mmHg 74 ± 12 82 ± 8 0.09
Office BP < 140/90 mmHg, n (%) 28 (59.6) 7 (30.4) 0.02
24 h SBP, mmHg 118 ± 12 124 ± 9 0.04
24 h DBP, mmHg 71 ± 7 74 ± 7 0.10
Cardiovascular organ damage
LVMi, g/m2 85 ± 17 98 ± 23 0.01
LVH, % 10 (21.7) 12 (52.2) 0.01
EF, % 63 ± 7 62 ± 8 0.65
LAVi, mL/m2 30 ± 9 28 ± 9 0.32
TDI e’, cm/s 8.0 ± 1.7 7.1 ± 1.4 0.04
E/e’ 8.7 ± 2.4 9.3 ± 3.0 0.38
GLS, % −20.96 ± 2.08 −20.72 ± 2.72 0.74
cf-PWV, m/s 7.5 ± 1.6 8.5 ± 1.7 0.02
* Quantitative values are expressed as mean ± SD or median [interquantile range]; BMI = body mass index;
SBP = systolic blood pressure; DBP = diastolic blood pressure; LVMi = left ventricular mass indexed to body
surface area; LVH = left ventricular hypertrophy; EF = ejection fraction; LAVi = left atrial volume indexed to body
surface area; E = transmitral Doppler E wave velocity; TDI = Tissue Doppler Imaging; e’ = TDI e’ wave velocity;
GLS = global longitudinal strain; cf-PWV = carotid-femoral pulse wave velocity.
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Figure 1. Cardiovascular organ damage in patients with and without cardiovascular adverse events
during follow up. LVMi = left ventricular mass indexed to body surface area (A); cf-PWV =
carotid-femoral pulse wave velocity (B). CVAEs = cardiovascular adverse events.
Likewise, we observed that patients with baseline LVH and cfPWV ≥ 9 m/s had an increased
incidence of CVAEs compared to those who had normal LVMi and cf-PWV < 9 m/s at first visit (55% vs.
23%, p = 0.003, and 53% vs. 25%, p = 0.02, respectively). Cf-PWV = 9 m/s was chosen as the most
sensitive cut-off by creating a ROC curve. Similarly, CVAEs rate was significantly higher when baseline
BP was uncontrolled (47% vs. 20%, p = 0.046).
Finally, we found the presence of at least one of these conditions (LVH, cf-PW ≥ 9 m/s,
BP ≥ 140/90 mmHg) was sensitive in recognizing who would experience CVAEs (Figure 2): we assigned
a score to each patient based on the presence (score = 1) or absence (score = 0) of each parameter
and we saw a significantly lower incidence of CVAEs in patients with a score = 0 (12%) compared to
patients with a score ≥ 1 (47%), p = 0.008.
Cancers 2019, 11, x 6 of 12 
 
 
Figure 1. Cardiovascular organ dam ge in patients with and without cardiovascular   
during follow up. LVMi = left ventricular mass indexed to bo y surface area (A); cf-PWV = carotid-
femor l pulse wave velocity (B). CVAEs = cardiovascular adverse events. 
Like ise, e observed that patients ith baseline L  and cfP  ≥ 9 /s had an increased 
incidence of CVAEs compared to those who had normal LVMi and cf-PWV < 9 m/s at first visit 
(55% vs. 23%, p = 0.003, and 53  vs. 25%, p = 0.02, respectively). Cf-PWV = 9 m/s was chosen as the 
most sensitive cut-off by creating a ROC curve. Similarly, CVAEs rate was significantly higher 
when baseline BP was uncontrolled (47% vs. 20%, p = 0.046). 
Finally, e found the presence of at least one of these conditions (LVH, cf-PW ≥ 9 m/s, BP ≥ 
140/90 mmHg) was sensitive in recognizing who would experience CVAEs (Figure 2): e assigned 
a score to each patient based on the presence (score = 1) or absence (score = 0) of each parameter and 
we saw a significantly lower incidence of CVAEs in patients with a score = 0 (12 ) co pared to 
patients ith a score ≥ 1 (47 ), p = 0.008. 
 
Figure 2. Kaplan Meier curves in multiple myeloma (MM) patients with (score ≥ 1) or without (score 
= 0) baseline uncontrolled hypertension, left ventricular hypertrophy or cf-PWV ≥ 9 m/s. LVH = left 
ventricular hypertrophy; cf-PWV = pulse wave velocity; BP = blood pressure. 
BP control represented the most sensitive parameter in recognizing patients at risk of 
developing CVAEs (BP sensitivity 70%), while LVH and cf-PWV allowed us to reach a higher 
i . Kaplan M ier curves in multiple myeloma (MM) patients with (score ≥ 1) or with ut
(score = 0) baseline uncontroll d hypertension, left ventricular hype trophy or cf-PWV ≥ 9 m/s.
LVH = left ventricular hypertrophy; cf-PWV = pulse wave velocity; BP = blood pressure.
Cancers 2019, 11, 622 8 of 12
BP control represented the most sensitive parameter in recognizing patients at risk of developing
CVAEs (BP sensitivity 70%), while LVH and cf-PWV allowed us to reach a higher specificity and to be
more accurate. Furthermore, the score ≥ 1 was even more sensitive than BP control alone and enabled
us to identify patients that could develop adverse events after carfilzomib treatment with a sensitivity
of 87% and the same accuracy (63%) as BP control alone (Figure 3).
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Finally, 48 patients underwent a follow up clinical evaluation that was performed after a mean
period of 6 ± 2.6 months at our Echo Lab. The examination was primarily based on checking office
blood pressure values and optimizing the antihypertensive treatment if necessary.
Anthropometric variables did not change from the first visit. We observed an improvement in
blood pressure control: systolic and diastolic office blood pressure values were significantly lower
compared to the first evaluation (SBP 126 ± 14 mmHg vs. 136 ± 19 mmHg, p = 0.001; DBP 72 ± 9 mmHg
versus 78 ± 11 mmHg, p = 0.002) and the prevalence of patients with office blood pressure < 140/90
raised from 43% to 68% (p = 0.02). Patients treated with antihypertensive drugs were 66% (versus 46%
at baseline visit), with a greater number of medications per person.
4. Discussion
To the best of our knowledge, this is the first study aimed at evaluating the prognostic value of
parameters commonly used to determine cardiovascular organ damage in predicting the incidence of
cardiovascular adverse events in MM patients treated with carfilzomib.
In our cohort, the baseline clinical characteristics did not highlight significant differences between
patients that did and did not experience CVAEs during follow up, except for office blood pressure
control, which was optimized before carfilzomib start (BP < 140/90 mmHg was necessary to begin the
infusions). However, in our population, baseline left ventricular mass and cf-PWV were significantly
higher in patients who experienced CVEAs during carfilzomib therapy. Furthermore, we recognized
left ventricular hypertrophy, cf-PWV ≥ 9 m/s, and baseline uncontrolled office blood pressure as
parameters able to distinguish subjects with increased risk of developing CVAEs over time.
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Left ventricular hypertrophy is known to be a direct consequence of an elevated afterload;
several studies have demonstrated its independent predictive value on incidence of CVAEs over
time [12]. Carfilzomib is thought to determine a direct cardiac damage: myocardial cells are sensitive
to proteasome inhibitors because of the important role of the ubiquitine-proteasome system for their
metabolism; the inhibition of proteasome activity leads to myocardiocyte apoptosis [22]. Moreover,
carfilzomib-induced endothelial dysfunction causes arteriolar vasoconstriction because of reduced NO
levels [7]. Clinically, this could translate into a tendency to develop left ventricular remodeling and LVH,
as recently suggested in a longitudinal study on a cohort of MM patients treated with carfilzomib [23].
According to this evidence, MM patients with baseline cardiac organ damage, particularly LVH, could
be predisposed to develop CVAEs after treatment with carfilzomib, which is known to be cardio-toxic
and likely involved in additional cardiac remodeling.
The ubiquitine-proteasome system plays an important role in endothelial cells, too: the inhibition
of proteasome activity is associated with increased intracellular oxidative stress, reduced eNOS
activity [7], and accelerated vascular aging, characterized by arterial stiffness and atherosclerosis [24].
Previous studies have demonstrated that chemotherapeutic drugs, like anti-VEGF, cause arterial
hypertension through the reduction of endothelial NO levels and subsequent increase in peripheral
resistance, with a rise in cf-PWV during treatment [25].
A recent animal study [26] has also proved a spasmogenic effect of carfilzomib: after pretreatment
with this proteasome inhibitor, rabbit aortic strips had an increased basal tone compared to the
untreated ones and showed enhanced response to vasopressors and reduced vasodilatatory response
to vasodilator agents. These data might explain why patients with baseline increased arterial stiffness
and higher cf-PWV values might be predisposed to have CVAEs during carfilzomib treatment: the rise
in blood pressure levels, the most frequently reported adverse effect, could be determined by an
additional endothelial dysfunction and an increased carfilzomib-induced vascular tone on already
damaged and stiff vessels.
Left ventricular hypertrophy and cf-PWV are known predictors of CVAEs incidence in
different populations [12,27,28]. These parameters could probably be useful in the oncological
population as well [29,30], to help stratify their risk of experiencing cardiovascular adverse effects
during chemotherapy.
However, the results obtained in our 70-patient cohort are preliminary and need to be confirmed
by further investigation on a larger population of MM patients, in order to state with stronger evidence
the potential predictive value of such parameters.
As regards cardiovascular adverse events, in our population the incidence was 32.9%, but only
7.2% of patients had a grade ≥ 3 CVAE. In the overall cohort, 30% had arterial hypertension, and only
5.7% required a temporary interruption of chemotherapy. These data overlap with what has been
previously demonstrated in literature [5]. ASPIRE, ENDEAVOR, and FOCUS studies showed an
incidence of arterial hypertension of 11%–32% in patients treated with carfilzomib compared to those
that underwent different chemotherapeutic strategies [1–3].
The incidences of myocardial infarction and arrhythmias (1.4%) were similar to the ones described
in the literature [4]. Furthermore, we did not see any cases of heart failure, which usually follows
carfilzomib treatment in 4% of cases [4]. The low incidence of major CVAEs with the need of stopping
chemotherapy encourages the use of this new proteasome inhibitor.
Finally, patients who underwent a follow up evaluation better blood pressure control then during
their first visit: this is probably related to the optimization of the antihypertensive treatment.
Our intervention is likely to have determined a reduced incidence of major events in our
cohort: CVAEs after carfilzomib treatment in carefully followed patients from a cardiovascular health
standpoint can be limited to a mild–moderate worsening in blood pressure, allowing patients to
continue the oncological therapy.
The main limitation of this study is represented by the small cohort. However, it is important
to underline that this is the first study with the aim of systematically evaluating the cardiovascular
Cancers 2019, 11, 622 10 of 12
profile of MM patients undergoing carfilzomib treatment, in order to find predictors of adverse events
following chemotherapy. The second important limitation of the study is the short-term follow up.
Further evaluations are needed to determine the incidence of long-term CVAEs.
5. Conclusions
Our study demonstrated that a comprehensive cardiovascular evaluation and management in
patients undergoing carfilzomib treatment may help identify subjects at higher risk of experiencing
CVAEs during follow up and determine a low incidence of major CVAEs, which are mainly represented
by worsening in blood pressure control, necessitating the interruption of chemotherapy.
The results we obtained indicate that the presence of at least one among LVH, high cf-PWV,
and uncontrolled hypertension, before carfilzomib infusions, may have a predictive role in identifying
patients who are likely to experience CVAEs during treatment. Although BP control has proved to
be more sensitive than LVH and cf-PWV, performing a TTE and measuring cf-PWV can improve our
ability to correctly identify patients at risk of CVAEs compared to blood pressure control alone.
These findings are preliminary. If additional investigation on a larger cohort confirms the primary
results, these parameters may be included in the baseline evaluation of MM patients undergoing
carfilzomib treatment, helping differentiate subjects who need a more aggressive antihypertensive
treatment and a stricter follow up from the beginning.
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